Results 241 to 250 of about 275,402 (290)

Fixed Treatment Duration Mosunetuzumab in Patients With Relapsed or Refractory Follicular Lymphoma: Perspectives From US Advanced Practice Providers. [PDF]

J Adv Pract Oncol
Guerrero MR, Averill B, Clermont L, Pak S, Kiernan J, Wu M, Lai D, To I, Farighi R, Piela M.   +9 more
europepmc   +1 more source

Temporal dynamics of immune effector cell‐associated haematotoxicity: Linking early and late cytopenias after chimeric antigen receptor T cells

British Journal of Haematology, Volume 209, Issue 3, Page 1399-1403, September 2026.
Malvina Bichon, Roch Houot, Mana Alshehri, Guillaume Manson, Faustine Lhomme, Samuel Vic   +5 more
wiley   +1 more source

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study. [PDF]

Hemasphere
Cheah CY, Blombery P, Johnston A, Wight J, Lewis KL, Bennett R, Xie J, Vlachos S, Hunter SM, Gonzales J, Binks S, Seymour JF.   +11 more
europepmc   +1 more source

Mechanisms of resistance to macrophage checkpoint inhibitors in B‐cell non‐Hodgkin lymphoma

British Journal of Haematology, Volume 209, Issue 3, Page 1350-1353, September 2026.
Zachary Hunzeker, Francisco Javier de la Rosa, Andrey Tyshevich, Darya Shavronskaya, Julia Alesse, Noel English, Lizzie Sheehan, Nikita Syzrantsev, Alexander Nesmelov, Hans‐Guido Wendel, Paolo Strati   +10 more
wiley   +1 more source

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma. [PDF]

Blood Cancer J
Sharp J, Bhatta S, Huang JJ, Thomas CJ, Elghawy O, Fitzgerald L, Reef D, Teferra A, Voorhees TJ, Gupta S, Grover NS, Barta SK, Shadman M, Epperla N.   +13 more
europepmc   +1 more source

[Management of follicular lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2014
openaire   +2 more sources

Diversity in Translation: Equal Is Greater Than

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
Elvin T. Price, John A. Wagner
wiley   +1 more source

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

JAMA Oncol
Shadman M, LeBlanc M, Rimsza L, Leonard JP, Smith SM, Li H, Friedberg JW.   +6 more
europepmc   +1 more source

Follicular lymphoma

Nature Reviews Disease Primers, 2019
Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal centre (GC) B cell differentiation. FL represents ~5% of all haematological neoplasms and ~20-25% of all new non-Hodgkin lymphoma diagnoses in western countries.
Anas Younes, Annunziata Gloghini, Armando Lopez Guillermo   +2 more
exaly   +10 more sources

Some of the next articles are maybe not open access.

Related searches:

Follicular lymphomas

Critical Reviews in Oncology/Hematology, 2008
Follicular lymphomas constitute approximately 30% of all non-Hodgkin lymphomas. These lymphomas are characterized by at least partially follicular growth pattern, but diffuse areas may be present. The proportions of follicular or diffuse areas vary also from case to case, which seems to be associated with prognosis.
Umberto, Vitolo, Andrés J M, Ferreri, Silvia, Montoto   +2 more
openaire   +2 more sources